Biohaven Ltd. (BHVN) AI Stock Analysis

• Market Cap: $1.44B
• Dividend Yield: N/A
• Average Volume (3M): 2.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: N/A
• EPS Growth: 18.76%
• Country: US
• Employees: 256
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.21
• Shares Outstanding: 150,417,080
• 10 Day Avg. Volume: 2,757,488
• 30 Day Avg. Volume: 2,268,954
• PEG Ratio: 0.06
• Price to Book (P/B): 23.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.99
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -514.81
• Enterprise Value/Ebitda: -1.43
• 1Y Price Target: $20.44
• Price Target Upside: 113.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -3.04
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $9.50 ▼(-0.84% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is held down primarily by weak financial performance (no revenue, heavy losses, accelerating cash burn, and sharply higher leverage in 2025). Technicals are neutral-to-soft and valuation is difficult to support with a negative P/E. Recent corporate events provide some offset via added funding and pipeline catalyst messaging, but do not fully mitigate the underlying financial risk.

Positive Factors

Diversified degrader platforms & 2026 pivotal trials

Biohaven’s MoDE and TRAP degrader platforms, showcased in the investor presentation, create a scalable R&D engine targeting autoimmune and renal diseases. Upcoming 2026 pivotal starts (BHV-1400, BHV-1300) represent structural development milestones that can materially de-risk programs and enable long-term commercial optionality if successful.

$125M targeted equity financing strengthens runway

The targeted $125M raise meaningfully bolsters near-term liquidity to fund clinical programs and operations, extending runway and reducing immediate refinancing pressure. This durable capital injection supports execution of pivotal trials and platform advancement over the next several quarters.

Business model includes product sales and partner economics

Biohaven’s dual monetization model—direct product revenues when commercialized plus collaboration economics—provides multiple durable revenue pathways. This flexibility supports strategic choices (retain vs partner) that can optimize capital needs and amplify long-term cash generation once assets reach market.

Negative Factors

No revenue and large persistent net losses

The company reports no revenue while incurring very large, persistent losses. Without commercial sales, reliance on external funding is structural. Prolonged negative earnings erode equity value and constrain strategic flexibility, raising long-term viability risk until meaningful revenue streams materialize.

Accelerating negative operating and free cash flow

Operating and free cash flow are deeply negative and have worsened year-over-year, signaling accelerating cash burn. Because FCF tracks net losses closely, the drain is cash-based rather than purely accounting-driven, reducing runway and increasing the probability of future dilution or constrained program funding.

Sharp rise in leverage and weakened balance sheet

Leverage surged with debt near $279M and equity compressed to ~$52M, producing very high debt-to-equity. Falling assets and weakened equity reduce financial flexibility, elevate refinancing and covenant risk, and limit the company’s ability to absorb clinical setbacks or fund simultaneous development programs.

Biohaven Ltd. Business Overview & Revenue Model

Company Description

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

How the Company Makes Money

Biohaven makes money primarily through (1) product-related revenues from commercialized therapies where it holds commercialization rights and books net sales (i.e., revenue derived from distributing and selling its medicines, net of rebates, discounts, and returns), and (2) collaboration/partnering economics when it enters agreements that may include upfront payments, milestone payments tied to development/regulatory/commercial achievements, and royalties on partners’ sales where applicable. The mix between these streams depends on which assets are commercialized directly versus partnered or out-licensed. Specific figures, product-by-product revenue contributions, and the material terms of any current agreements are null.

Biohaven Ltd. Financial Statement Overview

Summary

Financials are very weak for a pre-revenue profile: no revenue, large persistent net losses (2024 -$846.4M; 2025 -$738.8M), and deeply negative operating/free cash flow (2025 OCF -$609.4M; FCF -$610.2M). Balance sheet risk rose materially in 2025 with debt up to $278.9M and equity down to $52.1M (~5.36x debt-to-equity), reducing financial flexibility.

Income Statement

The income statement remains very weak: the company reports no revenue across the annual periods provided, while losses are large and persistent. Net loss widened meaningfully from 2023 (-$408.2M) to 2024 (-$846.4M), then improved modestly in 2025 (-$738.8M), indicating some cost variability but no clear path to profitability without revenue scale. Overall, profitability and earnings trajectory are the key pressure points.

Balance Sheet

Balance sheet risk increased sharply in 2025 as debt rose to $278.9M while equity fell to $52.1M, driving leverage to very high levels (debt-to-equity ~5.36x). This is a major deterioration versus 2022–2024 when leverage was low and equity was much higher. Total assets declined from $615.1M (2024) to $451.4M (2025), and returns on equity are deeply negative due to ongoing losses, leaving limited cushion if cash burn persists.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow deeply in the red each year (2025 operating cash flow -$609.4M; free cash flow -$610.2M). Free cash flow worsened from 2023 (-$334.8M) to 2024 (-$586.5M) and again to 2025 (-$610.2M), signaling an accelerating cash burn profile. A relative positive is that free cash flow roughly tracks net loss (free cash flow to net income ~1.00–1.14x historically), suggesting losses are largely cash-based rather than being masked by large non-cash add-backs—however, that also underscores the funding need.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-4.14M	0.00	0.00	0.00	0.00
EBITDA	-727.46M	-877.26M	-429.14M	-566.55M	-217.51M
Net Income	-738.82M	-846.42M	-408.17M	-570.28M	-213.80M
Balance Sheet
Total Assets	451.45M	615.11M	513.21M	661.78M	142.06M
Cash, Cash Equivalents and Short-Term Investments	319.14M	485.99M	381.82M	465.34M	76.06M
Total Debt	278.86M	36.58M	30.88M	33.60M	3.24M
Total Liabilities	399.38M	191.67M	85.24M	123.01M	47.37M
Stockholders Equity	52.07M	423.44M	427.98M	538.77M	34.69M
Cash Flow
Free Cash Flow	-610.15M	-586.50M	-334.77M	-338.76M	-146.78M
Operating Cash Flow	-609.44M	-582.45M	-331.73M	-297.69M	-145.84M
Investing Cash Flow	300.56M	-244.97M	129.83M	-304.79M	944.00K
Financing Cash Flow	439.12M	677.77M	211.91M	767.60M	138.45M

Biohaven Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHVN, the sentiment is Negative. The current price of 9.58 is below the 20-day moving average (MA) of 10.92, below the 50-day MA of 11.46, and below the 200-day MA of 13.19, indicating a bearish trend. The MACD of -0.47 indicates Positive momentum. The RSI at 35.52 is Neutral, neither overbought nor oversold. The STOCH value of 25.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BHVN.

Biohaven Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCRX	70 Outperform	$2.06B	6.20	-76.45%	―	45.38%	92.85%
AUPH	70 Outperform	$1.85B	7.46	70.37%	―	20.62%	―
VCEL	66 Neutral	$1.65B	110.29	5.17%	―	14.05%	241.86%
EWTX	61 Neutral	$3.17B	-12.72	-31.97%	―	―	-5.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MNKD	49 Neutral	$853.44M	-27.17	-11.21%	―	17.44%	24.15%
BHVN	45 Neutral	$1.44B	-1.64	-688.89%	―	―	18.76%

Biohaven Ltd. Corporate Events

Biohaven highlights degrader platforms in new investor presentation

On January 12, 2026, Biohaven Ltd. announced it would deliver an investor presentation outlining progress and plans across its diversified drug development platforms, highlighting its MoDE and TRAP extracellular degrader technologies that leverage hepatic ASGPR to selectively remove disease-causing proteins while preserving the broader immune system. The presentation emphasized upcoming pivotal trial starts in 2026 for BHV-1400 in IgA nephropathy and BHV-1300 in Graves’ disease, showcased BHV-1400’s recognition by the nephrology community and alignment with updated KDIGO 2025 guidelines that prioritize early, Gd-IgA1–targeted intervention, and positioned Biohaven’s degrader portfolio and broader pipeline as a scalable, patient-friendly engine designed to drive near-term clinical catalysts and long-term value for stakeholders in autoimmune and renal disease markets.

The most recent analyst rating on (BHVN) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.

Biohaven Announces $125 Million Targeted Equity Financing

On January 6, 2026, Biohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at $10.00 per share in a block transaction under its existing at-the-market equity program. The deal is expected to provide Biohaven with $125 million in gross proceeds before expenses, bolstering its capital position through a sizable, targeted equity raise that underscores ongoing investor appetite for the company’s stock and supports its ability to fund operations and pipeline development.

The most recent analyst rating on (BHVN) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.